Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
LPTX.......................................................bottomplay.......................................https://stockcharts.com/h-sc/ui?s=lptx&p=W&b=5&g=0&id=p86431144783
.50s seems good for an entry after the brutal dump in some .54
Bad day today but when this gets the data results and they go to market on the drug, this is an easy 10x stock.
4's towards nxt update and jp conference almost a given, ANT
touchin' 3's again, so little vol needed, nxt update should be saweet imvho ANT
touched 3 again, small prelude of things to come, imosho ANT
hearin' some good things comin' our way, hmm, u got to pay to play, ANT
hooverin' above 3 bucks, ceo certainly gave them somethin' to think about, to be continued.... ANT
LPTX..........................https://stockcharts.com/h-sc/ui?s=LPTX&p=W&b=5&g=0&id=p86431144783
held first support, startin' to like this one more and more, gild support, fyi ANT
consistent buyin' often means deeper pockets like what they see or are about to find out, so they add while it's cheap, imo but we'll see soon, ANT
because it's a double digitland stock, xcellent results will propel it imosho ANT
Any clue what's driving this major upside move the last week?
LPTX..........................https://stockcharts.com/h-sc/ui?s=LPTX&p=W&b=5&g=0&id=p86431144783
LPTX...................................https://stockcharts.com/h-sc/ui?s=LPTX&p=W&b=5&g=0&id=p86431144783
LPTX.......................................https://stockcharts.com/h-sc/ui?s=LPTX&p=W&b=5&g=0&id=p86431144783
LPTX................................https://stockcharts.com/h-sc/ui?s=LPTX&p=W&b=5&g=0&id=p86431144783
Wow..almost a year and no one posted anything!!
No one in their right mind gives 2 Sheets what some joke analyst gives for any price target
They are Shills
LPTX Piper ups Leap Therapeutics target to $6 following DKN-01's ASCO GI Update Jan. 23
Piper Sandler analyst Joseph Catanzaro raised the firm's price target on Leap Therapeutics (LPTX) to $6 from $5 and keeps an Overweight rating on the shares. Following the ASCO GI update for DKN-01, Leap hosted a conference call on Friday to walk through the data and lay out potential next steps, the analyst notes. When considering potential treatment effect, Catanzaro thinks the signal in DKK1-high patients looks even more compelling. Leap believes it could initiate a small randomized Phase II as part of the current IND that could generate data in 2023, while simultaneously engaging regulatory agencies on registrational strategies. Most notably, BeiGene's (BGNE) opt-in decision for Asian rights will almost certainly be a 2022 event, and the analyst continues to believe the ASCO GI update should make that a straightforward choice.
yep, something big happening here.
Followers
|
36
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
283
|
Created
|
02/03/17
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |